NCT05276310 2026-04-21
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
ImmuneOncia Therapeutics Inc.
Phase 1 Recruiting
ImmuneOncia Therapeutics Inc.
University of Rochester
Bristol-Myers Squibb
Weill Medical College of Cornell University
Shanghai Allink Biotherapeutics Co., Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Weill Medical College of Cornell University
Singapore General Hospital
University of Colorado, Denver
Canadian Cancer Trials Group
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.